Logo image of XNCR

XENCOR INC (XNCR) Stock Fundamental Analysis

NASDAQ:XNCR - Nasdaq - US98401F1057 - Common Stock - Currency: USD

15.74  -0.05 (-0.32%)

After market: 15.89 +0.15 (+0.95%)

Fundamental Rating

3

Overall XNCR gets a fundamental rating of 3 out of 10. We evaluated XNCR against 572 industry peers in the Biotechnology industry. While XNCR seems to be doing ok healthwise, there are quite some concerns on its profitability. XNCR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

XNCR had negative earnings in the past year.
XNCR had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: XNCR reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: XNCR reported negative operating cash flow in multiple years.
XNCR Yearly Net Income VS EBIT VS OCF VS FCFXNCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M -100M

1.2 Ratios

The Return On Assets of XNCR (-20.15%) is better than 77.80% of its industry peers.
The Return On Equity of XNCR (-27.39%) is better than 80.46% of its industry peers.
Industry RankSector Rank
ROA -20.15%
ROE -27.39%
ROIC N/A
ROA(3y)-3.3%
ROA(5y)-3.15%
ROE(3y)-5.06%
ROE(5y)-4.55%
ROIC(3y)N/A
ROIC(5y)N/A
XNCR Yearly ROA, ROE, ROICXNCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10

1.3 Margins

XNCR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XNCR Yearly Profit, Operating, Gross MarginsXNCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

XNCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XNCR has more shares outstanding
Compared to 5 years ago, XNCR has more shares outstanding
XNCR has a worse debt/assets ratio than last year.
XNCR Yearly Shares OutstandingXNCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
XNCR Yearly Total Debt VS Total AssetsXNCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.58, we must say that XNCR is in the distress zone and has some risk of bankruptcy.
XNCR has a Altman-Z score of 1.58. This is in the better half of the industry: XNCR outperforms 69.27% of its industry peers.
The Debt to FCF ratio of XNCR is 0.69, which is an excellent value as it means it would take XNCR, only 0.69 years of fcf income to pay off all of its debts.
XNCR has a better Debt to FCF ratio (0.69) than 95.91% of its industry peers.
XNCR has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
XNCR has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: XNCR outperforms 41.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.69
Altman-Z 1.58
ROIC/WACCN/A
WACC9.43%
XNCR Yearly LT Debt VS Equity VS FCFXNCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 6.23 indicates that XNCR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.23, XNCR is in the better half of the industry, outperforming 62.88% of the companies in the same industry.
A Quick Ratio of 6.23 indicates that XNCR has no problem at all paying its short term obligations.
XNCR has a better Quick ratio (6.23) than 63.23% of its industry peers.
Industry RankSector Rank
Current Ratio 6.23
Quick Ratio 6.23
XNCR Yearly Current Assets VS Current LiabilitesXNCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

XNCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.80%.
XNCR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.39%.
Measured over the past years, XNCR shows a very strong growth in Revenue. The Revenue has been growing by 32.90% on average per year.
EPS 1Y (TTM)-60.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-77.5%
Revenue 1Y (TTM)-41.39%
Revenue growth 3Y11.12%
Revenue growth 5Y32.9%
Sales Q2Q%-81.9%

3.2 Future

The Earnings Per Share is expected to grow by 1.68% on average over the next years.
XNCR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.04% yearly.
EPS Next Y-77.85%
EPS Next 2Y-28.47%
EPS Next 3Y-9.58%
EPS Next 5Y1.68%
Revenue Next Year-68.93%
Revenue Next 2Y-25.04%
Revenue Next 3Y-8.27%
Revenue Next 5Y4.04%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XNCR Yearly Revenue VS EstimatesXNCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
XNCR Yearly EPS VS EstimatesXNCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6 8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XNCR. In the last year negative earnings were reported.
Also next year XNCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XNCR Price Earnings VS Forward Price EarningsXNCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, XNCR is valued cheaper than 94.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF 42.34
EV/EBITDA N/A
XNCR Per share dataXNCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

A cheap valuation may be justified as XNCR's earnings are expected to decrease with -9.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.47%
EPS Next 3Y-9.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XNCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XENCOR INC

NASDAQ:XNCR (2/21/2025, 8:00:02 PM)

After market: 15.89 +0.15 (+0.95%)

15.74

-0.05 (-0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-03 2025-03-03/amc
Inst Owners108.35%
Inst Owner Change5.24%
Ins Owners0.81%
Ins Owner Change0.24%
Market Cap1.10B
Analysts83.33
Price Target33.57 (113.28%)
Short Float %7.65%
Short Ratio8.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.72%
Min EPS beat(2)-19.61%
Max EPS beat(2)29.05%
EPS beat(4)1
Avg EPS beat(4)-67.88%
Min EPS beat(4)-243.57%
Max EPS beat(4)29.05%
EPS beat(8)4
Avg EPS beat(8)-18.33%
EPS beat(12)7
Avg EPS beat(12)108.86%
EPS beat(16)10
Avg EPS beat(16)105.39%
Revenue beat(2)1
Avg Revenue beat(2)-7.99%
Min Revenue beat(2)-20.99%
Max Revenue beat(2)5.02%
Revenue beat(4)1
Avg Revenue beat(4)-25.24%
Min Revenue beat(4)-44.31%
Max Revenue beat(4)5.02%
Revenue beat(8)4
Avg Revenue beat(8)4.8%
Revenue beat(12)7
Avg Revenue beat(12)31.27%
Revenue beat(16)11
Avg Revenue beat(16)47.24%
PT rev (1m)0%
PT rev (3m)-4.89%
EPS NQ rev (1m)3.14%
EPS NQ rev (3m)3%
EPS NY rev (1m)0.96%
EPS NY rev (3m)3.82%
Revenue NQ rev (1m)17.16%
Revenue NQ rev (3m)15.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.93
P/FCF 42.34
P/OCF 31.84
P/B 1.52
P/tB 1.56
EV/EBITDA N/A
EPS(TTM)-3.2
EYN/A
EPS(NY)-3.47
Fwd EYN/A
FCF(TTM)0.37
FCFY2.36%
OCF(TTM)0.49
OCFY3.14%
SpS1.22
BVpS10.34
TBVpS10.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.15%
ROE -27.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 30.55%
ROA(3y)-3.3%
ROA(5y)-3.15%
ROE(3y)-5.06%
ROE(5y)-4.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.69
Debt/EBITDA N/A
Cap/Depr 69.69%
Cap/Sales 10.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.23
Quick Ratio 6.23
Altman-Z 1.58
F-Score2
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)297.12%
Cap/Depr(5y)277.19%
Cap/Sales(3y)14.93%
Cap/Sales(5y)12.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-77.5%
EPS Next Y-77.85%
EPS Next 2Y-28.47%
EPS Next 3Y-9.58%
EPS Next 5Y1.68%
Revenue 1Y (TTM)-41.39%
Revenue growth 3Y11.12%
Revenue growth 5Y32.9%
Sales Q2Q%-81.9%
Revenue Next Year-68.93%
Revenue Next 2Y-25.04%
Revenue Next 3Y-8.27%
Revenue Next 5Y4.04%
EBIT growth 1Y-48.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-131.72%
EBIT Next 3Y-39.48%
EBIT Next 5Y-16.67%
FCF growth 1Y-63.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.72%
OCF growth 3YN/A
OCF growth 5YN/A